

Single-cell profiling of tumour evolution in multiple myeloma: implications for precision medicine

Nature Reviews Clinical Oncology

19, 223-236

DOI: [10.1038/s41571-021-00593-y](https://doi.org/10.1038/s41571-021-00593-y)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Dynamics of Nucleotide Variants in the Progression from Low-Intermediate Myeloma Precursor Conditions to Multiple Myeloma: Studying Serial Samples with a Targeted Sequencing Approach. <i>Cancers</i> , 2022, 14, 1035.	1.7	0
2	Anti-BCMA Immunotherapy in Myeloma: Is It the Tumor or the Immune System That Most Undermines Outcomes?. , 2022, 19, .		0
3	Multiple myeloma with high-risk cytogenetics and its treatment approach. <i>International Journal of Hematology</i> , 2022, 115, 762-777.	0.7	30
4	Emerging digital PCR technology in precision medicine. <i>Biosensors and Bioelectronics</i> , 2022, 211, 114344.	5.3	28
5	Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence. <i>Leukemia</i> , 2022, 36, 1887-1897.	3.3	23
6	A Novel Medication Decision Gene Signature Predicts Response to Individualized Therapy and Prognosis Outcomes in Hepatocellular Carcinoma Patients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
7	The Role of Clonal Evolution on Progression, Blood Parameters, and Response to Therapy in Multiple Myeloma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
9	The Urgent Need for Precision Medicine in Cancer and Its Microenvironment: The Paradigmatic Case of Multiple Myeloma. <i>Journal of Clinical Medicine</i> , 2022, 11, 5461.	1.0	2
10	Current perspectives on interethnic variability in multiple myeloma: Single cell technology, population pharmacogenetics and molecular signal transduction. <i>Translational Oncology</i> , 2022, 25, 101532.	1.7	1
11	Single-cell transcriptome sequencing reveals potential novel combination of biomarkers for antibody-based cancer therapeutics in hepatocellular carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
12	A novel medication decision gene signature predicts response to individualized therapy and prognosis outcomes in hepatocellular carcinoma patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
13	Development of a versatile high-throughput mutagenesis assay with multiplexed short-read NGS using DNA-barcoded supF shuttle vector library amplified in <i>E. coli</i> . <i>ELife</i> , 0, 11, .	2.8	3
14	Hotspots and trends in multiple myeloma bone diseases: A bibliometric visualization analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
15	Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis. <i>Nature Communications</i> , 2022, 13, .	5.8	14
16	High precision, high throughput generation of droplets containing single cells. <i>Lab on A Chip</i> , 2022, 22, 4841-4848.	3.1	4
17	MSC Senescence-Related Genes Are Associated with Myeloma Prognosis and Lipid Metabolism-Mediated Resistance to Proteasome Inhibitors. <i>Journal of Oncology</i> , 2022, 2022, 1-17.	0.6	3
18	MinimuMM-seq: Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma Pathology. <i>Cancer Discovery</i> , 2023, 13, 348-363.	7.7	4
19	Amp(1q) and tetraploidy are commonly acquired chromosomal abnormalities in relapsed multiple myeloma. <i>European Journal of Haematology</i> , 2023, 110, 296-304.	1.1	3

#	ARTICLE	IF	CITATIONS
20	What about (MG)US? Towards tailored testing in monoclonal gammopathies. <i>Haematologica</i> , 0, , .	1.7	0
21	Deep transfer learning enables lesion tracing of circulating tumor cells. <i>Nature Communications</i> , 2022, 13, .	5.8	8
22	The cellular biology of plasma cells: unmet challenges and opportunities. <i>Immunology Letters</i> , 2023, , .	1.1	0
23	A narrative review for platelets and their RNAs in cancers: New concepts and clinical perspectives. <i>Medicine (United States)</i> , 2022, 101, e32539.	0.4	0
24	Dynamic single-cell RNA-seq analysis reveals distinct tumor program associated with microenvironmental remodeling and drug sensitivity in multiple myeloma. <i>Cell and Bioscience</i> , 2023, 13, .	2.1	4
26	<i>In Situ</i> Polymerization of Aniline Derivative <i>In Vivo</i> for NIR-II Phototheranostics of Tumor. <i>ACS Applied Materials & Interfaces</i> , 2023, 15, 5870-5882.	4.0	3
27	Prognostic Relevance of Multi-Antigenic Myeloma-Specific T-Cell Assay in Patients with Monoclonal Gammopathies. <i>Cancers</i> , 2023, 15, 972.	1.7	1
28	Noncoding RNAs in the crosstalk between multiple myeloma cells and bone marrow microenvironment. <i>Cancer Letters</i> , 2023, 556, 216081.	3.2	1
29	The prognostic utility of dynamic risk stratification at disease progression in patients with multiple myeloma. <i>Hematology</i> , 2023, 28, .	0.7	3
30	SCMcluster: a high-precision cell clustering algorithm integrating marker gene set with single-cell RNA sequencing data. <i>Briefings in Functional Genomics</i> , 2023, 22, 329-340.	1.3	2
32	AIMedGraph: a comprehensive multi-relational knowledge graph for precision medicine. <i>Database: the Journal of Biological Databases and Curation</i> , 2023, 2023, .	1.4	2
33	Periplocin Overcomes Bortezomib Resistance by Suppressing the Growth and Down-Regulation of Cell Adhesion Molecules in Multiple Myeloma. <i>Cancers</i> , 2023, 15, 1526.	1.7	1
34	Characteristics and Risk Factors of Ultra-High-Risk Patients with Newly Diagnosed Multiple Myeloma. <i>Journal of Personalized Medicine</i> , 2023, 13, 666.	1.1	0